对于许多患者来说，癌症连续体包括一种称为癌症相关恶病质 (CAC) 的综合征，其中包括体重和肌肉质量的意外下降，并且通常与脂肪减少、食欲下降、耐受性降低和治疗反应较差有关，生活质量差，生存率降低。不幸的是，没有有效的治疗干预措施可以完全逆转癌症恶病质，也没有 FDA 批准的药物；因此，迫切需要新的方法。 2022 年 5 月，莫菲特癌症中心的研究人员和临床医生举办了 CAC 首次务虚会，旨在回顾科学现状、确定知识差距和研究重点，并促进跨学科合作研究项目。这篇综述总结了这次务虚会中出现的研究重点、正在进行的合作的例子以及推动科学前进的机会。确定的最高优先事项包括需要 (1) 评估在临床实践中获得的患者报告结果 (PRO) 测量并评估其在改善 CAC 相关结果中的用途； (2) 确定生物标志物（影像、分子和/或行为）和新的分析方法，以准确预测 CAC 的早期发病及其进展； (3) 制定和测试干预措施（药理学、营养、运动以及通过数学模型）以预防 CAC 进展并改善相关症状和结果。

For many patients, the cancer continuum includes a syndrome known as cancer-associated cachexia (CAC), which encompasses the unintended loss of body weight and muscle mass, and is often associated with fat loss, decreased appetite, lower tolerance and poorer response to treatment, poor quality of life, and reduced survival. Unfortunately, there are no effective therapeutic interventions to completely reverse cancer cachexia and no FDA-approved pharmacologic agents; hence, new approaches are urgently needed. In May of 2022, researchers and clinicians from Moffitt Cancer Center held an inaugural retreat on CAC that aimed to review the state of the science, identify knowledge gaps and research priorities, and foster transdisciplinary collaborative research projects. This review summarizes research priorities that emerged from the retreat, examples of ongoing collaborations, and opportunities to move science forward. The highest priorities identified include the need to (1) evaluate patient-reported outcome (PRO) measures obtained in clinical practice and assess their use in improving CAC-related outcomes; (2) identify biomarkers (imaging, molecular, and/or behavioral) and novel analytic approaches to accurately predict the early onset of CAC and its progression; and (3) develop and test interventions (pharmacologic, nutritional, exercise-based, and through mathematical modeling) to prevent CAC progression and improve associated symptoms and outcomes.